BioRestorative Therapies (BRTX) said Thursday that the US Food and Drug Administration has cleared its investigational new drug application for BRTX-100 to potentially treat chronic cervical discogenic pain.
BioRestorative Chief Executive Officer Lance Alstodt said the company is planning to carry out a phase 2 study to evaluate BRTX-100's safety and preliminary efficacy in patients with chronic cervical discogenic pain "as soon as is practicable."
Price: 1.87, Change: -0.04, Percent Change: -2.09
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。